232 related articles for article (PubMed ID: 28350084)
21. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
22. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
[TBL] [Abstract][Full Text] [Related]
24. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
25. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
Kwon JH; Lee N; Park JY; Yu YS; Kim JP; Shin JH; Kim DS; Joh JW; Kim DS; Choi KY; Kang KJ; Kim G; Moon YH; Wang HJ
PLoS One; 2013; 8(6):e64260. PubMed ID: 23785399
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
Abeni E; Salvi A; Marchina E; Traversa M; Arici B; De Petro G
Int J Oncol; 2017 Jul; 51(1):128-144. PubMed ID: 28560380
[TBL] [Abstract][Full Text] [Related]
27. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.
Song M; Cheng H; Zou H; Ma K; Lu L; Wei Q; Xu Z; Tang Z; Zhang Y; Wang Y; Sun C
BMC Cancer; 2024 Jun; 24(1):673. PubMed ID: 38825709
[TBL] [Abstract][Full Text] [Related]
29. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma.
Yang L; Zhang Z; Sun Y; Pang S; Yao Q; Lin P; Cheng J; Li J; Ding G; Hui L; Li Y; Li H
Aging (Albany NY); 2020 Nov; 12(23):23849-23871. PubMed ID: 33221766
[TBL] [Abstract][Full Text] [Related]
30. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
31. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
[TBL] [Abstract][Full Text] [Related]
32. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.
Lee M; Kim K; Kim SY; Jung SH; Yoon J; Kim MS; Park HC; Jung ES; Chung YJ; Lee SH
Hum Pathol; 2018 Nov; 81():37-46. PubMed ID: 29949741
[TBL] [Abstract][Full Text] [Related]
33. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
34. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.
Liu J; Ma Q; Zhang M; Wang X; Zhang D; Li W; Wang F; Wu E
Eur J Cancer; 2012 Oct; 48(15):2328-38. PubMed ID: 22459764
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
36. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Arizumi T; Ueshima K; Takeda H; Osaki Y; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
[TBL] [Abstract][Full Text] [Related]
37. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
[TBL] [Abstract][Full Text] [Related]
38. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
[TBL] [Abstract][Full Text] [Related]
39. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
